Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3390 | Robot Assisted Percutaneous Cardiovascular Intervention Wiki | 0.33 |
| drug3080 | PressureWire X Wiki | 0.33 |
| drug3342 | Resolute Onyx Wiki | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3805 | Supera 7.5 OD stent Wiki | 0.33 |
| drug1870 | ISIS 721744 Wiki | 0.33 |
| drug299 | Anthocyanins Wiki | 0.33 |
| drug288 | Angiography Wiki | 0.33 |
| drug1873 | IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care. Wiki | 0.33 |
| drug215 | Ad5FGF-4 Wiki | 0.33 |
| drug2803 | Pacel BPC Wiki | 0.33 |
| drug1872 | IV Dexamethasone Wiki | 0.33 |
| drug2804 | Pacel FDPC Wiki | 0.33 |
| drug2258 | MULTI-LINK 8 LL stent Wiki | 0.33 |
| drug2437 | Motivational social support from nurse with additional support from significant other Wiki | 0.33 |
| drug1882 | Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus Wiki | 0.33 |
| drug2436 | Motivational social support from nurse Wiki | 0.33 |
| drug2501 | Nasal Dexamethasone Wiki | 0.33 |
| drug158 | AVP 4 Wiki | 0.33 |
| drug396 | Attention control Wiki | 0.33 |
| drug4322 | Xpert Pro stent Wiki | 0.33 |
| drug185 | Absolute Pro LL stent Wiki | 0.33 |
| drug26 | 12 weeks of bicycle exercise Wiki | 0.33 |
| drug3918 | Tele-medicine platform Wiki | 0.33 |
| drug1881 | Icosapent ethyl (IPE) Wiki | 0.33 |
| drug1291 | DynamX Bioadaptor Wiki | 0.33 |
| drug3165 | QFR Wiki | 0.33 |
| drug2259 | MULTI-LINK 8 SV stent Wiki | 0.33 |
| drug159 | AVP I Wiki | 0.33 |
| drug160 | AVP II Wiki | 0.33 |
| drug4319 | XIENCE PRIME BTK stent Wiki | 0.33 |
| drug2260 | MULTI-LINK 8 stent Wiki | 0.33 |
| drug1880 | Icosapent ethyl Wiki | 0.24 |
| drug545 | Best Practice Wiki | 0.15 |
| drug2616 | Normal Saline Wiki | 0.14 |
| drug514 | Baricitinib Wiki | 0.13 |
| drug1193 | Dexamethasone Wiki | 0.11 |
| drug4025 | Tocilizumab Wiki | 0.05 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003324 | Coronary Artery Disease NIH | 1.00 |
| D009203 | Myocardial Ischemia NIH | 0.52 |
| D000787 | Angina Pectoris NIH | 0.47 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007511 | Ischemia NIH | 0.47 |
| D003327 | Coronary Disease NIH | 0.38 |
| D023921 | Coronary Stenosis NIH | 0.33 |
| D023903 | Coronary Restenosis NIH | 0.33 |
| D060050 | Angina, Stable NIH | 0.33 |
| D006331 | Heart Diseases NIH | 0.27 |
| D054143 | Heart Failure, Systolic NIH | 0.24 |
| D054058 | Acute Coronary Syndrome NIH | 0.14 |
| D007676 | Kidney Failure, Chronic NIH | 0.13 |
| D003704 | Dementia NIH | 0.12 |
| D007238 | Infarction NIH | 0.10 |
| D006333 | Heart Failure NIH | 0.10 |
| D008173 | Lung Diseases, Obstructive NIH | 0.09 |
| D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.09 |
| D060825 | Cognitive Dysfunction NIH | 0.09 |
| D020521 | Stroke NIH | 0.08 |
| D004617 | Embolism NIH | 0.08 |
| D002318 | Cardiovascular Diseases NIH | 0.06 |
| D007249 | Inflammation NIH | 0.06 |
| D009369 | Neoplasms, NIH | 0.06 |
| D013577 | Syndrome NIH | 0.03 |
| D007239 | Infection NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001658 | Myocardial infarction HPO | 0.52 |
| HP:0001681 | Angina pectoris HPO | 0.47 |
| HP:0005145 | Coronary artery stenosis HPO | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000726 | Dementia HPO | 0.12 |
| HP:0001635 | Congestive heart failure HPO | 0.10 |
| HP:0006536 | Pulmonary obstruction HPO | 0.09 |
| HP:0001268 | Mental deterioration HPO | 0.09 |
| HP:0006510 | Chronic pulmonary obstruction HPO | 0.09 |
| HP:0001297 | Stroke HPO | 0.08 |
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.06 |
| HP:0002664 | Neoplasm HPO | 0.06 |
Navigate: Correlations HPO
There are 9 clinical trials
The purpose of this study is to determine whether a single intracoronary infusion of an adenovirus serotype 5 virus expressing the gene for human fibroblast growth factor-4 (Ad5FGF-4) is effective in improving angina-limited exercise duration, angina functional class, frequency of angina attacks, frequency of nitroglycerin usage, and quality of life. Half of the study participants will receive Ad5FGF-4, and half will receive placebo. The primary endpoint is the change from baseline to Month 6 in Exercise Tolerance Test (ETT) duration. Long-term safety of Ad5FGF-4 will also be assessed.
Description: Modified Bruce Protocol with exercise duration limited by angina or angina equivalent
Measure: Change in Exercise Tolerance Test (ETT) duration Time: Baseline and Month 6Description: Canadian Cardiovascular Society (CCS) angina classification
Measure: Change in patient functional status (CCS class) Time: Baseline and Month 6Description: Average weekly angina episodes
Measure: Change in weekly angina frequency Time: Baseline and Month 6Description: Average weekly nitroglycerin usage
Measure: Change in weekly nitroglycerin usage Time: Baseline and Month 6Description: Seattle Angina Questionnaire
Measure: Change in quality of life Time: Baseline and Month 6Description: Adverse events and clinical laboratory testing
Measure: Safety of Ad5FGF-4 Time: Through Month 6Description: Occurrence of clinically significant events
Measure: Long-term safety of Ad5FGF-4 Time: Through Month 60The aim of this project is to study the safety and efficacy of anthocyanins in improving key dementia-related mechanisms and cognitive functioning in older people at risk for dementia. Secondary analyses will include a variety of biological measures, including biochemistry, imaging and cardiovascular measures.
Description: A composite measure from the CogTrack battery
Measure: Quality of episodic memory. Time: Baseline to 24 weeksDescription: CogTrack evaluates attentional intensity index, sustained intensity index, cognitive reaction time, attentional fluctuation index, quality of working memory, quality of episodic memory and speed of memory retrieval.
Measure: Secondary endpoints from CogTrack Time: Baseline to 24 weeksDescription: Lipid profile, fatty acids, cytokines ( among others: IL-1, IL-2, IL-6, TNF-a), plasma antoxidant status and vitamins (lipid peroxidation markers, vitamins E, C, A, total plasma antioxidant capacity, glutathion)., carinthine, blood glucose, HbA1c, anthocyanins and metabolites, mapping of a-beta degradation products.
Measure: Blood outcome analysis Time: Baseline to 24 weeksDescription: Flow-mediated dilation (FMD), Cardiac-ankle vascular index (CAVI), photoplethysmogram (PPG).
Measure: Cardiovascular parameters Time: Baseline to 24 weeksDescription: Microbiota
Measure: Fecal analysis Time: Baseline to 24 weeksDescription: kyrinin
Measure: Urine analysis Time: Baseline to 24 weeksDescription: anthocyanin metabolites
Measure: CSF measurements Time: Baseline to 24 weeksDescription: Diagnosing and follow-up of cerebrovascular disease
Measure: MR-imaging/CT Time: Baseline to 24 weeksThe overall purpose of the FAVOR III China trial is to investigate if a strategy of quantitative flow ratio (QFR)-guided percutaneous coronary intervention (PCI) yields superior clinical outcome and cost-effectiveness compared to a strategy of standard coronary angiography-guided PCI in evaluation of patients with coronary artery disease.
Description: A composite of all-cause mortality, any myocardial infarction and any ischemia-driven revascularization
Measure: MACE Time: 1 yearDescription: all-cause mortality, any spontaneous myocardial infarction and any ischemia-driven revascularization
Measure: MACE excluding peri-procedural MI (Major secondary endpoint) Time: 1 yearDescription: Cardiovascular, non-cardiovascular and undetermined death
Measure: Death Time: 1 month, 6 months, 1 year, 2 years and 3 yearsDescription: Target vessel related and non-target vessel related MI
Measure: MI Time: 1 month, 6 months, 1 year, 2 years and 3 yearsDescription: The ischemia driven and non-ischemia driven TVR
Measure: Target vessel revascularization (TVR) Time: 1 month, 6 months, 1 year, 2 years and 3 yearsDescription: The The ischemia driven and non-ischemia driven Revascularization
Measure: Any coronary artery revascularization Time: 1 month, 6 months, 1 year, 2 years and 3 yearsDescription: Definite and probable stent thrombosis during acute, sub-acute, late, and very late phase according to the Academic Research Consortium (ARC)-2
Measure: Definite or probable stent thrombosis Time: 1 month, 6 months, 1 year, 2 years and 3 yearsDescription: PCI strategy changes following QFR and three-dimension quantitative coronary angiography (3D-QCA)
Measure: The PCI strategy changes based on the QFR and 3D-QCA Time: During the procedureDescription: Costs include direct clinical costs during the initial hospitalization and other resources used, main cardiovascular medication expenses, and outpatient and/or hospitalization expenses associated with MACE.
Measure: Cost during 1-year follow-up Time: 1 month, 6 months, 1 yearDescription: QALYs determined using EuroQol five dimensions questionnaire (EQ-5D) in official Chinese version, to assess the quality of life.
Measure: Quality-adjusted-life-years (QALYs) index Time: 1 month, 6 months, 1 yearAfter a 30-year decline, heart disease is projected to increase up to 18% by 2030. Participation rates in cardiac rehabilitation remain extremely low and hopeless individuals are less likely to participate. This innovative study has the potential to advance science, improve patient care, and improve patient outcomes by demonstrating the effectiveness of the Heart Up! program to increase physical activity and reduce hopelessness in patients with heart disease. Hopelessness is associated with a 3.4 times increased risk of mortality or nonfatal myocardial infarction in patients with ischemic heart disease (IHD), independent of depression. Hopelessness has been identified in 27-52% of patients with IHD and can persist for up to 12 months after hospital discharge. Hopelessness, a negative outlook and sense of helplessness toward the future, can be a temporary response to an event (state) or a habitual outlook (trait). Hopelessness is associated with decreased physical functioning and lower physical activity (PA) levels in individuals with IHD. While research has investigated strategies to increase PA among IHD patients in general, the study team is the only group to design an intervention to promote PA specifically in hopeless IHD patients. The purpose of this randomized controlled trial is to establish the effectiveness of our 6-week mHealth intervention (Heart Up!) to promote increased PA in hopeless patients with IHD. A total of 225 hopeless IHD patients will be enrolled from a large community teaching hospital in the Midwest. Patients will be randomized (75 per group) to one of three groups: 1) motivational social support (MSS) from a nurse, 2) MSS from a nurse with additional significant other support (SOS), or 3) attention control (AC). It is hypothesized that 1) The MSS with SOS group will have the greatest increase in average minutes of moderate to vigorous PA per day at 8 and 24 weeks as compared to the MSS only or AC groups; 2) Greater increase in minutes of moderate to vigorous PA per day will be associated with decreased state hopelessness levels from baseline to weeks 8 and 24; and 3) Increased social support and increased motivation will mediate the effects of Heart Up! on a greater increase in moderate to vigorous PA at 8 and 24 weeks. The findings from this study could transform care for IHD patients who are hopeless by promoting self-management of important PA goals that can contribute to better health outcomes.
Description: Mean minutes/day moderate to vigorous physical activity
Measure: ActiGraph GT9X Link Accelerometer Time: Month 12Description: Participant's report of current level of state hopelessness. Total score range= 1 (better) to 4 (worse).
Measure: State-Trait Hopelessness Scale Time: Month 12Description: Participant's report of exercise self-regulation level. Total score range= 1 (worse) to 7 (better).
Measure: Exercise Self-Regulation Questionnaire Time: Month 12Description: Participant's report of perceived social support level. Total score range= 1 (worse) to 30 (better).
Measure: ENRICHD Social Support Inventory Time: Month 12Description: Comorbidity score based on medical record abstraction. Total score range= 0 (better) to 100 (worse).
Measure: Charlson Comorbidity Index Time: Week 1Description: Participant's report of participation level with exercise in home, community or cardiac rehabilitation program
Measure: Cardiac Rehabilitation Exercise Participation Tool Time: Month 12Description: Participant's report of mean level of depressive symptoms. Total score range= 0 (better) to 27 (worse).
Measure: Patient Health Questionnaire-9 Time: Month 12Description: Participant's report of mean level of well-being. Total score range= 4 (better) to 20 (worse).
Measure: PROMIS-29 Time: Month 12Description: Participant's report of mean level state and trait hope. Total score range= 8 (worse) to 64 (better).
Measure: Snyder State Trait Scales Time: Month 12Description: Participant's report of mean level of quality of life. Total score range= 1 (better) to 5 (worse).
Measure: EuroQol (EQ-5d-5L) Time: Month 12Description: Participant's report of COVID-19 symptoms, diagnosis, testing, and social distancing. No score range (14 items).
Measure: Multi-Ethnic Study of Atherosclerosis (MESA) COVID-19 Questionnaire Time: Month 12Description: Participant's report of impact on routine; income/ employment; access to food, medical and mental health care, extended family; and stress. No range (12 items)
Measure: Coronavirus Impact Scale Time: Month 12Management of known patients with cardiovascular disease (in particular the whole spectrum of atherosclerotic ischaemic coronary artery disease, essential hypertension under treatment, and also patients with chronic heart failure under medication) and with other associated chronic pathologies, with obvious effects on the management of the pandemic with modern / distance means (e-Health) of patients at high risk of mortality in contact with coronavirus. Given the Covid-19 Pandemic, all the above complex cardiovascular patients are under the obligation to stay in the house isolated and can no longer come to standard clinical and paraclinical monitoring and control visits. Therefore, a remote management solution (tele-medicine) of these patients must be found. The Investigators endeavour is to create an electronic platform to communicate with these patients and offer solutions for their cardiovascular health issues (including psychological and religious problems due to isolation). The Investigators intend to create this platform for communicating with a patient and stratify their complaints in risk levels. A given specialist will sort and classify their needs on a scale, based on specific algorithms (derived from the clinical European Cardiovascular Guidelines), and generate specific protocols varying from 911 like emergencies to cardiological advices or psychological sessions. These could include medication changing of doses, dietary advices or exercise restrictions. Moreover, in those patients suspected of COVID infection, special assistance should be provided per protocol.
Description: Development of an electronic (e-HEALTH) framework structure for management of patients with known cardiovascular disease in COVID19 pandemic social context
Measure: Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients Time: 6 monthsDescription: patients come into direct contact with the case coordinator, who provides ongoing assistance, including for connecting to devices that ensure real-time data transmission and directing to specialist teams that establish stage diagnosis and management / therapy behavior (including adjustment). doses, decisions to discontinue medication or to add medication);
Measure: Number of patients included in this platform Time: 6 monthsDescription: Will be the number of sessions per patient multiplied with the number of patients included
Measure: Number of consultations/sessions given Time: 6 monthsThis phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.
Description: The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will be tested by Cochran-Mantel-Haenszel (CMH) test stratified by the age group and Sequential Organ Failure Assessment (SOFA) score at significance level of 0.05.
Measure: 7-day length of invasive mechanical ventilation (MV) Time: Up to 7 daysDescription: Defined as death within 30-day after randomization. The 30-day mortality rate for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: 30-day mortality rate Time: Up to 30-day after randomizationDescription: The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of intensive care (ICU) transfer Time: Up to 2 yearsDescription: The rate of invasive mechanical ventilation for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of invasive mechanical ventilation Time: Up to 2 yearsDescription: The rate of tracheostomy for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of tracheostomy Time: Up to 2 yearsDescription: Will first be described by median and inter-quartile, and then compared between two arms by Wilcoxon Sum-Rank test
Measure: Length of ICU stay Time: Up to 2 yearsPercutaneous cardiovascular intervention procedures (e.g. coronary angioplasty, peripheral artery angioplasty) must be performed in person, requiring the physical presence of one or more medical, nursing and technical professionals. The control of catheters and interventional materials is performed manually, with the operator positioned next to the patient. This context results in potential for reciprocal exposure to exhaled air, both for the professionals involved and for the patient, with an inherent risk of aerial contamination. It is important to note that interventional procedures are often performed on an urgent or emergency basis (e.g. myocardial infarction), without the possibility of postponement or postponement. The recent robot-assisted cardiovascular intervention makes it possible to modify this scenario by allowing the procedure to be performed effectively and safely in a position far from the patient. In an environment with high potential for contamination, mainly related to the current pandemic caused by the COVID-19 virus, may prove to be a tactic to expand hospital security. It is in this sense that the present pilot proposal is inserted, which, ultimately, aims to evaluate the potential of robotic intervention as a strategy to reduce exposure to exhaled air of patients and professionals during the intervention procedure.
Description: (arterial dilation with residual lesion <50% at angiography and normal anterograde flow)
Measure: Successful cardiovascular intervention Time: Until the end of the procedureThe Infinity-Swedeheart trial is a prospective, multicenter, single-blind, randomized registry-based clinical trial. Eligible patients will be randomized 1:1 (DynamX Bioadaptor : Resolute Onyx).
Description: Device Oriented Clinical Endpoint (DOCE) of target lesion failure (TLF; cardiovascular death, target vessel myocardial infarction (TV-MI), or ischemia-driven target lesion revascularization (ID-TLR))
Measure: Target Lesion Failure (TLF) Time: 1 yearDescription: Lesion-Level Analysis
Measure: Device Success Time: During Study ProcedureDescription: Patient-Level Analysis
Measure: Procedural Success Time: In-Hospital, assessed up to 7 daysDescription: Composite Device Oriented Clinical Endpoint (DOCE) (TLF; cardiovascular death, TV-MI, ischemia-driven TLR)
Measure: Composite Rate of Device Oriented Clinical Endpoint (DOCE) Time: 30 days, 6 months, 1-5 yearsDescription: Composite Patient Oriented Clinical Endpoint (POCE) (all-cause mortality, any stroke, any myocardial infarction (includes non-target vessel territory) and any revascularization). Note: Stroke to be collected and included in the POCE at 1 year and 5 years only.
Measure: Composite Rate of Patient Oriented Clinical Endpoint (POCE) Time: 30 days, 6 months, 1-5 yearsDescription: Target vessel failure (TVF; cardiovascular death, target vessel myocardial infarction (TV-MI), or target vessel revascularization (TVR))
Measure: Rate of Target Vessel Failure (TVF) Time: 30 days, 6 months, 1-5 yearsDescription: Composite of cardiovascular death, any myocardial infarction and any revascularization
Measure: Composite Rate of cardiovascular death, any myocardial infarction and any revascularization Time: 30 days, 6 months, 1-5 yearsDescription: Ischemia driven target lesion revascularization (ID-TLR)
Measure: Rate of Ischemia driven target lesion revascularization (ID-TLR) Time: 30 days, 6 months, 1-5 yearsDescription: All Target Lesion Revascularization
Measure: Rate of Target Lesion Revascularization (TLR) Time: 30 days, 6 months, 1-5 yearsDescription: All Target Vessel Revascularization
Measure: Rate of Target Vessel Revascularization (TVR) Time: 30 days, 6 months, 1-5 yearsDescription: Ischemia driven target vessel revascularization (ID-TVR)
Measure: Rate of Ischemia driven target vessel revascularization (ID-TVR) Time: 30 days, 6 months, 1-5 yearsDescription: Ischemia driven non target vessel revascularization (ID-NTVR)
Measure: Rate of Ischemia driven non target vessel revascularization (ID-NTVR) Time: 30 days, 6 months, 1-5 yearsDescription: Non target vessel revascularization (NTVR)
Measure: Rate of Non target vessel revascularization (NTVR) Time: 30 days, 6 months, 1-5 yearsDescription: All revascularization
Measure: Rate of All revascularization Time: 30 days, 6 months, 1-5 yearsDescription: All MI, Q-Wave and Non Q-Wave MI, TV-MI, NTV-MI
Measure: Rate of Myocardial Infarction Time: 30 days, 6 months, 1-5 yearsDescription: Cardiovascular Death, All-Cause Death
Measure: Rate of Death Time: 30 days, 6 months, 1-5 yearsDescription: Composite: Cardiovascular death or myocardial infarction
Measure: Composite: Cardiovascular death or myocardial infarction Time: 30 days, 6 months, 1-5 yearsDescription: Composite: All-cause death or myocardial infarction
Measure: Composite: All-cause death or myocardial infarction Time: 30 days, 6 months, 1-5 yearsDescription: Composite: All-cause death, myocardial infarction or target vessel revascularization
Measure: Composite: All-cause death, myocardial infarction or target vessel revascularization Time: 30 days, 6 months, 1-5 yearsDescription: Any stroke (collected at 1 year and 5 years only)
Measure: Rate of any stroke Time: 1 year and 5 yearsDescription: Anginal Status by Seattle Angina Questionnaire-7 (SAQ-7)
Measure: Anginal Status Time: 30 days and 1 yearDescription: Composite: Probable or definite stent thrombosis Probable Stent Thrombosis Definite Stent Thrombosis
Measure: Rate of Stent Thrombosis Time: 30 days, 6 months, 1-5 yearsThe AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the devices in scope within their intended use with the aim of confirming safety and performance throughout their expected lifetime, ensuring the continued acceptability of identified risks, detecting emerging risks on the basis of factual evidence, ensuring the continued acceptability of the benefit-risk ratio, and identifying possible systematic misuse or off-label usage such that the intended use can be verified as appropriate.
Description: Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive XIENCE BTK and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, and TLR Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive XIENCE BTK and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, and TLR Time: 30 daysDescription: Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive XIENCE BTK and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, and TLR Time: 12 monthsDescription: Composite of all-cause death, amputation, TLR, target lesion occlusion will be assessed among the patients who receive Absolute Pro LongLength (LL), Supera 7.5 Outer Diameter (OD), Xpert Pro and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, TLR, target lesion occlusion Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of all-cause death, amputation, TLR, target lesion occlusion will be assessed among the patients who receive Absolute Pro LongLength (LL), Supera 7.5 Outer Diameter (OD), Xpert Pro and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, TLR, target lesion occlusion Time: 30 daysDescription: Composite of all-cause death, amputation, TLR, target lesion occlusion will be assessed among the patients who receive Absolute Pro LongLength (LL), Supera 7.5 Outer Diameter (OD), Xpert Pro and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, TLR, target lesion occlusion Time: 12 monthsDescription: Composite of potential complications including implant success,occlusion success, migration will be assessed among the patients whoreceive AVP or AVP II or AVP 4 and its competitors.
Measure: Number of participants with composite of potential complications (Implant success, occlusion success,migration) Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of vessel dissection, perforation, and thromboembolism during procedure will be assessed among the patients who receive PressureWire X and its competitors.
Measure: Number of participants with composite of vessel dissection, perforation, and thromboembolism Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Signal drift (minimal pressure drift > 3 mmHg) will be assessed among the patients who receive PressureWire X and its competitors.
Measure: Number of participants with signal drift (minimal pressure drift > 3 mmHg) Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Loss of capture (average time of loss of capture across patients) will be assessed among the patients who receive Pacel FDPC and its competitors.
Measure: Loss of capture Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of potential complications (venous thrombosis, pulmonaryemboli, arrhythmias, perforation) will be assessed among the patientswho receive Pacel BPC and its competitors.
Measure: Number of participants with composite of potential complications (venous thrombosis, pulmonaryemboli, arrhythmias, perforation) Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of all-cause death, MI or target lesion revascularization(TLR) will be assessed among the patients who receive MULTI-LINK 8or MULTI-LINK 8 LL or MULTI-LINK 8 SV and its competitors.
Measure: Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR) Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of all-cause death, MI or target lesion revascularization(TLR) will be assessed among the patients who receive MULTI-LINK 8or MULTI-LINK 8 LL or MULTI-LINK 8 SV and its competitors.
Measure: Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR) Time: 30 daysDescription: Composite of all-cause death, MI or target lesion revascularization(TLR) will be assessed among the patients who receive MULTI-LINK 8or MULTI-LINK 8 LL or MULTI-LINK 8 SV and its competitors.
Measure: Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR) Time: 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports